{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-013289","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2022-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.917900+00:00","generated_at":"2026-06-24T07:38:25.746842+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cyclerion CY6463 shows cognition effect size 0.60 in CIAS study; well tolerated","bullets":["Effect size 0.60 on Cogstate Schizophrenia Battery composite after 14 days of 15 mg CY6463 vs placebo.","No SAEs, severe AEs, or discontinuations due to AEs; all adverse events transient.","Favorable changes observed in broad panel of plasma inflammatory biomarkers linked to schizophrenia.","48 adults with stable schizophrenia on single atypical antipsychotic; PK linear dose-proportional.","Company exploring partnerships; webinar July 28 at 8:00 a.m. EDT to discuss data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-013289","json":"https://secwatch.observer/filing/0000950170-22-013289.json","markdown":"https://secwatch.observer/filing/0000950170-22-013289.md","text":"https://secwatch.observer/filing/0000950170-22-013289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022013289/0000950170-22-013289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000095017022013289/cycn-20220728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:38:25.746842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}